Baidu
map

Nat Chem Biol:新型抗菌化合物可有效抵御耐药病原体且毒性较低

2015-06-04 佚名 生物谷

靶向攻击真菌感染而不损伤人类细胞的新型化合物或许可以有效避免抗生素耐药性的产生;近日,刊登在国际杂志Nature Chemical Biology上的一篇研究论文中,来自伊利诺伊大学的研究人员通过研究开发并且检测了抗真菌药物两性霉素B的多种衍生物。两性霉素B医生们推出的最后一道抵御真菌感染的防御性药物,该药已经使用了近半个世纪,其被认为可以有效克服新生的耐药性病原体的感染。 研究者Burke表

靶向攻击真菌感染而不损伤人类细胞的新型化合物或许可以有效避免抗生素耐药性的产生;近日,刊登在国际杂志Nature Chemical Biology上的一篇研究论文中,来自伊利诺伊大学的研究人员通过研究开发并且检测了抗真菌药物两性霉素B的多种衍生物。两性霉素B医生们推出的最后一道抵御真菌感染的防御性药物,该药已经使用了近半个世纪,其被认为可以有效克服新生的耐药性病原体的感染。

研究者Burke表示,该药物的主要问题就是毒性较大,尤其是对于肾脏的伤害,因此限制该药的剂量对于治疗病人非常重要;此前研究发现两性霉素B可以通过靶向作用对细菌生理活性重要的脂质分子来杀灭酵母和真菌,但该药物同时也会结合人类机体的胆固醇,从而引发机体毒性。

这项研究中,研究者进行了三步简单的化学步骤,将两性霉素B转化成了一种新型化合物,这种化合物可以有效靶向作用真菌的脂质分子,但其并不结合胆固醇分子;随后研究者发现这种特殊衍生物可以抵御小鼠机体的酵母感染,而且对小鼠并不带来任何毒性作用。由于该药物的作用效果较为特殊,因此研究者担心是否会出现耐药性菌株,当对突变的耐药性酵母进行试验后,研究者发现这种衍生物同样也可以对耐药性菌株进行作用。

研究者表示,两性霉素B躲避病原体耐药性的特殊能力或许和其毒性之间存在不寻常的关系,因此他们就推测这些衍生物或许并没有两性霉素B那么容易受到影响,这对于开发新型的抵御耐药性病原体感染的疗法或许非常重要。

研究者希望本文研究可以帮助他们寻找更多可以抵御耐药性真菌感染以及低毒性的化合物,这对于有效杀灭耐药性病原体,同时改善患者的机体健康和生活质量将非常重要。

原始出处:

Stephen A Davis, Benjamin M Vincent, Matthew M Endo, Luke Whitesell, Karen Marchillo, David R Andes, Susan Lindquist & Martin D Burke.Nontoxic antimicrobials that evade drug resistance.Nature Chemical Biology, June 1, 2015.doi:10.1038/nchembio.1821

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2016-05-05 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2016-01-10 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1906301, encodeId=1206190630157, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Sun May 15 18:09:00 CST 2016, time=2016-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880684, encodeId=b3221880684ab, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 05 17:09:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766945, encodeId=d3741e669452a, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jan 22 15:09:00 CST 2016, time=2016-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917160, encodeId=4589191e160fb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jan 10 21:09:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330522, encodeId=e0d3133052283, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510617, encodeId=401d151061ec4, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Sat Jun 06 00:09:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-06 xue8605

相关资讯

NEJM:腹腔感染后短程抗生素治疗效果

背景:成功治疗腹腔感染,需要源头控制和抗生素的结合。但抗生素治疗的适当时间尚不清楚。      方法:研究人员招募了518例复杂腹腔感染患者,所有患者都在出现退烧、白细胞增多和肠梗阻2天后接受抗生素治疗,并且有适当的源控制。实验组接受固定抗生素治疗4±1天,对照组接受较长(最长达10天)的治疗期。根据治疗组情况,主要观察结果是手术部位感染,以及反复腹腔感染时或源控

Sci trans med:新一代抗生素成功抵抗耐药菌

基于结构对早期使用的抗生素奇霉素进行化学修饰,科学家们研发出了新一代奇霉素抗生素。第二代奇霉素能抑制对各种抗生素耐受的肺炎链球菌的生长,并对导致呼吸道疾病的嗜血杆菌和卡塔莫拉菌的抗菌能力增强,对军团杆菌和性传播的淋球菌和衣原体的抗菌能力也有所增强。 细菌的耐药性问题越来越严重,正常剂量的药物无法发挥应有的杀菌效果,给疾病的治疗造成困难。目前认为抗药性的产生是微生物基因突变造成的。为防止和减少抗药

Cell Host & Microbe:抗生素,儿科失调和疾病

最近来自明尼苏达大学的科学家通过研究揭示了婴儿期抗生素使用、肠道菌群改变及婴儿后期疾病状况之间的三角关系,相关研究发表于Cell Host & Microbe上;肠道菌群失衡即为生态失调,往往会引发多种感染性疾病、过敏症及其它字体免疫障碍,甚至肥胖等。该研究或为临床开发一种预测性的模型来测定幼儿肠道中健康菌群的发育提供帮助。抗生素是目前针对儿童最常用的处方药,其在儿童服用的所有药物中大约占

震惊!江浙沪儿童一半以上暴露于抗生素

近日,上海复旦大学公共卫生学院公布一份有关“江浙沪儿童普遍暴露于多种抗生素”的研究报告,引起公众广泛关注。这项研究,历经1年,对江苏、浙江、上海1000多名8到11岁在校儿童的尿液监测证实,该地儿童普遍暴露于多种抗生素,背负沉重的抗生素负担。 化验结果让人震惊 有的甚至被检出6种抗生素 化验结果表明,这1000多个样本儿童中,至少有

Mol Microbiol:揭秘耐药菌毒力因子的特殊结构单元或可开发新型抗生素

近日,一项发表于国际杂志Molecular Microbiology上的研究论文中,来自阿德莱德大学的科学家通过研究发现了一种新型靶点,该靶点或为开发抵御引发疾病细菌的新型抗生素提供一定的帮助;文章中研究者鉴别出了对许多细菌毒力因子较为常见的结构单元,细菌的毒力因子是一种可以引发疾病的特殊蛋白质,比如毒素类或降解酶。 这种结构单元名为“旅客”相关的运输重复结构(PATR,Passenger-

世卫组织通过抗微生物药物耐药性决议

第68届世界卫生大会25日通过应对抗微生物药物耐药性决议,敦促世界卫生组织各成员重视抗微生物药物面临的耐药性问题并采取行动。    世卫组织称,出现在全世界各地的抗微生物药物耐药性(包括抗生素耐药性)是最为紧迫的抗药趋势,它削弱了治疗传染性疾病的能力和其他许多卫生与医药方面的进展。    这项名为“抗微生物药物耐药性全球行动计划”的决议设

Baidu
map
Baidu
map
Baidu
map